Nab-paclitaxel as second-line treatment in advanced biliary cancer

被引：0
|
作者：
Unseld, M. [1 ]
Kornek, G. [2 ]
Werner, S. [2 ]
Guenther, S. [2 ]
Christoph, Z.
Gerald, P.
机构：
[1] Med Univ Vienna, Oncol, Vienna, Austria
[2] MUW, Oncol, Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31215-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2299
引用
收藏
页码：S431 / S432
页数：2
相关论文
共 50 条
  • [1] Nab-paclitaxel as second-line treatment in advanced biliary cancer.
    Prager, Gerald W.
    Kornek, Gabriela
    Scheithauer, Werner
    Steger, Guenther G.
    Zielinski, Christoph
    Unseld, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] Second-line nab-paclitaxel for advanced urothelial carcinoma
    Sarah Payton
    Nature Reviews Urology, 2013, 10 (8) : 431 - 431
  • [3] Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer
    Li, Xiaofen
    Zhou, Nan
    Yang, Yu
    Lu, Zijian
    Gou, Hongfeng
    CANCER SCIENCE, 2024, 115 (07) : 2371 - 2383
  • [4] Capecitabine and Nab-Paclitaxel as Second-Line Treatment for Advanced Biliary Tract Cancer (ABTC): Results from a Phase II Pilot Study
    Leighton, Carly
    Brungs, Daniel
    Sjoquist, Katrin
    Chantrill, Lorraine
    Grimison, Peter
    Tognela, Annette
    Aghmesheh, Morteza
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 127 - 127
  • [5] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Yasin
    Karhan, Ogur
    Aldemir, Mehmet Naci
    Urun, Muslih
    Ercek, Berrak Mermit
    Urakci, Zuhat
    Arvas, Hayati
    Tunc, Sezai
    Erdem, Mehmet
    Yerlikaya, Halis
    Ileri, Serdar
    Aydin, Ibrahim
    Bicer, Abdurrahman
    Komuroglu, Ahmet Ufuk
    Majidova, Nargiz
    Gokcek, Savas
    Demir, Hacer
    Yildiz, Sedat
    Akbas, Sinem
    Ozen, Esra
    Kahya, Burcu Ulas
    Sali, Muersel
    Anik, Hicran
    Aykut, Talat
    Araz, Murat
    Alkan, Ali
    Ozcelik, Melike
    Sakin, Abudllah
    Aykan, Musa Baris
    Mehtiyev, Mirmehdi
    Demir, Bilgin
    Baser, Mehmet Nuri
    Sonmez, Muge
    Gulturk, Ilkay
    Avci, Niluever
    Urvay, Semiha
    Arici, Mustafa Ozgur
    Kalender, Mehmet Emin
    Yildirim, Mustafa
    Solmaz, Ali Alper
    Gurbuz, Mustafa
    Ergun, Yakup
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [6] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Y.
    Karhan, O.
    Urakci, Z.
    Mecidova, N.
    Araz, M.
    Sakin, A.
    Ercek, B. M.
    Urun, M.
    Urvay, S.
    Aykan, M. B.
    Kocak, S.
    Arici, M. O.
    Avci, N.
    Alkan, A.
    Ozcelik, M.
    Aldemir, M. N.
    Ergun, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S930 - S930
  • [7] A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer
    Hosein, Peter J.
    Lopes, Gilberto de Lima, Jr.
    Pastorini, Vitor H.
    Gomez, Christina
    Macintyre, Jessica
    Zayas, Gloria
    Reis, Isildinha
    Montero, Alberto J.
    Merchan, Jaime R.
    Lima, Caio M. Rocha
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2013, 36 (02): : 151 - 156
  • [8] The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Cheng, Xiaojiao
    Li, Qingli
    Tu, Shuiping
    Chen, Xiaobing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [9] Nab-paclitaxel plus ramucirumab combination therapy as second-line with advanced gastric cancer:Retrospective study
    Kashiwada, Tomomi
    Nishioka, Atsujiro
    Komiya, Kazutoshi
    Aragane, Naoko
    Kimura, Shinya
    ANNALS OF ONCOLOGY, 2019, 30 : 140 - 140
  • [10] Efficacy of Nab-Paclitaxel as Second-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
    Fukuchi, Minoru
    Mochiki, Erito
    Ishiguro, Toru
    Ogura, Toshiro
    Sobajima, Jun
    Kumagai, Youichi
    Ishibashi, Keiichiro
    Ishida, Hideyuki
    ANTICANCER RESEARCH, 2016, 36 (12) : 6699 - 6703
12345